Obese young adults are at increased risk of pancreatic cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Young adults who are overweight or obese have an increased risk of pancreatic cancer, according to a study out of M.D. Anderson Cancer Center. In addition, the Houston-based researchers found that obesity at an older age is associated with a lower overall survival rate for patients with pancreatic cancer.

Young adults who are overweight or obese have an increased risk of pancreatic cancer, according to a study out of M.D. Anderson Cancer Center. In addition, the Houston-based researchers found that obesity at an older age is associated with a lower overall survival rate for patients with pancreatic cancer. Donghui Li, PhD, and colleagues studied the associations between body mass index (BMI) over a lifetime and pancreatic cancer risk, age at onset, and overall patient survival. The study included 841 patients with pancreatic cancer and 754 healthy individuals matched by age, race, and sex. Height and body weight histories were collected by personal interview starting at ages 14 and taking place over 10-year intervals progressing to the year prior to recruitment (JAMA 301:2553-2562, 2009).

They found that individuals who were overweight (a BMI of 25-29.9) from the ages of 14 to 39 years or obese (a BMI of 30 or greater) from the ages of 20 to 49 years had an associated increased risk of pancreatic cancer, independent of diabetes status. The association between average BMI (per five-unit increase) and risk of pancreatic cancer was stronger in men than in women.

Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Related Content